Viron is a private company pioneering the development of viral protein therapeutics to treat and prevent human inflammatory disorders. Viral proteins represent a revolutionary new class of drugs. Viron's approach provides competitive advantages by providing numerous unique product development opportunities. Viron's pipeline of compounds, across all stages of development, combined with a robust discovery program and strong intellectual property base, positions the Company to be a leader in the discovery and commercialization of bio-therapeutics.
In June of 2006, Viron closed a Series ‘A' financing of $20 million USD to accelerate Viron programs. Viron's two largest shareholders remain GrowthWorks Capital and Barvest Inc.
Viron is currently seeking options (M&A or financing) to fund Company operations to the middle of 2014. Target milestones over the next two years include:
- VT-111a Phase 1b/2a clinical study of 160 patients to repeat and extend the findings from the previous study
- Generation of new targeted therapeutics from PROSPECTTM discovery platform
- Advancement of pipeline programs
- Building Viron team to support the next phase of growth
Inquiries
Should you be interested in discussing investment opportunities, please contact:
Kevin Sullivan
Chief Operating Officer
By Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
By Mail:
Viron Therapeutics Inc.
700 Collip Circle, Suite 203
London, ON Canada
N6G 4X8
By Telephone: 519.858.5109
